Mesh-ID,
Automated digital
onboarding

Mesh ID is a trust-tech software company with a focus on solutions for the global trust and corporate services industry. Their blockchain-based solutions enable clients to achieve operational excellence by meeting their regulatory compliance requirements faster, and better, than before. In this way, Mesh ID helps Venture Capital and Private Equity funds launch quickly by reducing the time to on-board investors from months to minutes.

Clients of Mesh ID include fund managers and their LPs, corporations, fund and corporate services administrators, custodian banks, law firms, and notaries. Alongside their clients, governments and licensing authorities trust Mesh ID technology to enhance customer onboarding, increase data security, improve operating cost models, and mitigate compliance risk.

We invested in Mesh ID from our Evergreen Fund.

Our news

9 April, 2026

819 Capital Partners invests in Wolk

Deventer, 9 April 2026 - Dutch company Wolk has raised €1.75 million to accelerate the deployment of its smart hip airbag in elderly care. The investment round was led by 819 Capital Partners, through 819 Seed Fund I, and the Innovatiefonds Ouderenzorg of CbusineZ (CZ), with participation from Nivogé, Catalyst Impact Investment Club, and several angel investors. Each year in the Netherlands, approximately 120,000 elderly people end up in the emergency department after a fall....

Continue reading
6 March, 2026

819 Capital Partners acquires key assets of Lead Pharma, enabling continuation of operations

Deventer, 6 March 2026 - 819 Capital Partners has acquired the key assets of Lead Pharma, thereby realizing a continuation based on the company’s patent portfolio and associated research programs. The transaction includes intellectual property rights, research data, and selected development programs. Lead Pharma develops innovative small-molecule medicines for the treatment of cancer and autoimmune diseases. Over the past years, the company built a strong research platform and multiple drug candidates, collaborating with international pharmaceutical companies...

Continue reading